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ABSTRACT
Topically applied therapy is the most common way to treat ocular diseases, however given the anatomical and physiological constraints
of the eye, frequent dosing is required with possible repercussions in terms of patient compliance. Beyond refractive error correction,
contact lenses (CLs) have, in the last few decades emerged as a potential ophthalmic drug controlled release system (DCRS). Extensive
research is underway to understand how to best modify CLs to increase residence time and bioavailability of drugs within therapeutic
levels on the ocular surface. These devices may simultaneously correct ametropia and have a role in managing ophthalmic disorders that
can hinder CL wear such as dry eye, glaucoma, ocular allergy and cornea infection and injury. In this narrative review the authors
explain how the ocular surface structures determine drug diffusion in the eye and summarize the strategies to enhance drug residence
time and bioavailability. They synthesize findings and clinical applications of drug soaked CLs as DCRS combined with delivery
diffusion barriers, incorporation of functional monomers, ion related controlled release, molecular imprinting, nanoparticles and
layering. The authors draw conclusions about the impact of these novel ophthalmic agents delivery systems in improving drug transport
in the target tissue and patient compliance, in reducing systemic absorption and undesired side effects, and discuss future perspectives.
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RESUMO
A forma mais frequente de aplicação terapêutica em oftalmologia consiste na instilação de gotas oculares, mas dadas as limitações
anatómicas e fisiológicas do olho, é necessária dosagem frequente com possível repercussão na adesão do paciente à terapêutica. Nas
últimas décadas, as lentes de contacto (CLs)  têm surgido como um potencial sistema de libertação controlada de fármacos na
superfície ocular (DCRS)  para correção do erro refrativo. Está em curso uma extensa investigação para entender a melhor forma
de modificar as CLs, de modo a aumentar o tempo de residência e a biodisponibilidade do medicamento na superfície ocular dentro
de níveis terapêuticos. Ao corrigirem a ametropia, estes dispositivos poderão simultaneamente desempenhar um  papel na gestão de
perturbações oftalmológicas, tais como a síndrome do olho seco, glaucoma, alergia ocular e infecção corneana, que podem compro-
meter o porte seguro e confortável das CLs. Nesta revisão narrativa, os autores explicam como as estruturas da superfície ocular
determinam a difusão de fármacos no olho e sintetizam as estratégias para aumentar a permanência e biodisponibilidade dos
mesmos.  Em seguida, apresentam os resultados e as aplicações clínicas das CLs embebidas em fármacos, como DCRS, através da
incorporação de barreiras de difusão, de monómeros funcionais, da liberação controlada por iões, da impressão molecular, de
nanopartículas e pelo processo camada sobre camada. Os autores concluem avaliando o impacto destes novos sistemas de entrega
de agentes farmacológicos ao melhorar o seu transporte no tecido alvo, reduzindo a sua absorção sistémica e os seus efeitos
colaterais indesejáveis,   e discutem perspectivas futuras.
Descritores:  Lentes de contacto; Síndrome de olho seco; Glaucoma; Alergia; Queratite; Biodisponibilidade; Tempo de perma-
nência; Impressão molecular; Nanopartículas
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INTRODUCTION
P oly (methyl methacrylate) (PMMA) was the firstsuccessful polymeric contact lense (CL) materialintroduced in the market in the 1960s. These CLs are
rigid, time consuming to fit and not very comfortable to wear.
Research into new types of polymers led to the development of
hydrogels, the first biomaterials designed for clinical use. They
consist of a cross-linked polymeric network with a high capacity
of water absorption and have been extensively used in numerous
biomedical applications since the early 1960s. In 1965 Wichterle
at al. pioneered the suggestion of their potential use in ophthalmic
drug delivery as bandage soft CLs (SCL). Although the new
materials were quite hydrophilic, which kept the lens soft and
flexible, their gas-permeability was still low. The introduction of
highly permeable silicone hydrogel (SH) in the late 1990s
overcame SCLs’ insufficient oxygen transmission to the cornea.
SHCLs represented a significant leap for further research on
CLs as ophthalmic drug controlled release systems (DCRS). 1-4
Several factors emphasize their singular importance in the
field of ocular therapeutics: the approximately 125 million
worldwide CL wearers; well-studied CL biocompatibility and
transparency; the familiarity of their use with minimal effect on
ocular functions and a large residence time in the eye. Eye
physiological and anatomical constraints compromise the correct
drug concentration and optimal absorption of pharmacological
agents at the specific action site requiring multiple dosage of eye
drops eventually associated with noncompliance, overdosing and
unwanted systemic side effects. The latter are especially important
in chronic ocular diseases such as glaucoma, allergy and dry eye
as in those requiring a timely and effective control, as infectious
keratitis and corneal wound healing. 5-8
Drug Routes, Ocular Surface and Effectiveness Constraints
The three main routes of administration of ocular
medication are systemic, intraocular and topical. Effective
systemic delivery requires a high drug concentration to achieve
a therapeutically effective dose within the eye. Intraocular drug
administration is effective but as with any invasive procedure it
carries a not insignificant risk, especially if repeated treatments
are required. Topically applied medication represents
approximately 90% of aqueous ophthalmic formulations. They
are simple to formulate, have minimal storage limitations and
can be self-administered. However, significant drug losses occur
with this administration form, which limit its therapeutic efficiency.
Understanding the structure of the ocular surface, tear drainage
physiology and drug diffusion mechanisms can shed an
understanding on ocular drug pharmacokinetic and the reasons
for such inefficiency.  9,10
If the human tear film is approximately 7 ìl, a 30 ìl eye drop
is rapidly squeezed out of the eye, the remainder being mixed in
the tear volume with an estimated residence time of
approximately 2 - 3 minutes. The conjunctiva presents a higher
permeability than the cornea due to its vascularized nature and
an area that is approximately 16 - 18 times larger. Thus, most of
the solutes are absorbed by the conjunctiva, drained by the lacri-
mal system into the nose and enter the systemic circulation with
potential unwanted systemic side effects. In this context, only 1-
7% of the medication within an eye drop reaches the target
tissue with effective therapeutic effect thus justifying multiple
dosing over extended periods with potential association with
low compliance or drug overdosing. 3, 10, 11
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The precorneal tear film allows corneal hydration and
provides an epithelium-tear interface able to create a high
refractive index. It presents an inner mucous layer anchored by
microvilli to the epithelium, a middle aqueous layer with mucin
and free lipid and an external thin lipid layer. It is divided into
three compartments: precorneal, conjunctiva and tear menisci
and is bounded by the corneal and the conjunctiva epithelia.
CLs divide the tear film into a pre-lens tear film (PLTF) and a 4
micra thick post-lens tear film or pre-ocular tear film (POLTF),
through which CL drug diffusion occurs. Eye opening leads to a
limited drug release towards the PLTF and the CL motion
promotes drug diffusion from the POLTF into the cornea or
radially outwards from the CL into the tear lake. 10,
The cornea is a multilayer structure with epithelium, stroma,
and endothelium separated by the Bowman and Descemet’s
membranes. The cornea has both lipophilic and hydrophilic
properties, which explains a transport resistance to hydrophilic
drugs of approximately 90% and about 10% to hydrophobic
preparations. Corneal diffusion is the main route for topically
applied drug absorption leaving a lesser role for the conjunctival/
scleral route to play in. Corneal epithelium is a stratified layer
presenting Ca2+-dependent membrane adherent regions (zonula
occludens, zonula adherens and desmosomes) creating tight
junctions, highly resistant to drug diffusion. Bowman’s membrane
is a transitional and acellular structure approximately 8–14 ìm
thick. Corneal stroma is a gel-like layer with 80% of water, collagen,
mucopolysaccharides and proteins, and represents approximately
90% of the total thickness (around 500 ìm) of the cornea. Due to
solubility and partition coefficient limitation it shows significant
diffusion resistance for lipophilic drugs and minimal for
hydrophilic drugs.  Descemet’s membrane is an approximately 6
ìm thick membrane deposited by the endothelial cells. These
loose epithelia-like cells regulate stromal hydration and maintain
the cornea transparent. They form a monolayer of cells of about
13 ìm of thickness, the endothelium that provides little resistance
to paracellular drug transportation. 10, 12, 13
The conjunctiva comprises several layers of epithelial and
goblet cells that line the palpebral, culs de sac and the bulbar
ocular surface to the corneal limbus. Most of the apical epithelial
cells express mucin on their surface to create a protective
glycocalyx. Goblet cells secrete gel-forming mucins that are
relevant for eye lubrication and protection. The lacrimal gland
produces smaller mucins. Diffusion through conjunctival
epithelial cells follows a para-cellular path, ion channels, water
channels, co-transporters, and transport pumps for ion, glucose,
and water located in the cell membrane. 10, 13
Drainage of the tear film from the eye is an active process
that depends on blinking.3, 10
New delivery systems and devices to improve drug
bioavailability
Morrison and Khutoryanskiy categorize the strategies to
promote drug residence time and diffusion into the eye into
three groups: Drug Solubility and Penetration Enhancement,
Ocular Implants and Drug Retention from which we will
emphasize CLs14 (Table 1).
Hydrotropic compounds improve aqueous drug solubility
of poorly water-soluble compounds. Hydrotropes, such as
caffeine, urea and nicotinamide enhance the solubility of
riboflavin, while cyclodextrins form drug complexes with steroids,
carbonic anhydrase inhibitors, pilocarpine and cyclosporine A
(CyA), which are too large to partition to the cornea. Formulating
for higher drug concentration also increases bioavailability. The
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incorporation of compounds able to modify the corneal epithelia
improves drug penetration and tissue drug partitioning.
Benzalconium cloride  (BAC), commonly used as a preservative
in ocular drug formulations, cetylpyridinium chloride (CPC),
ethylenediaminetetraacetic acid (EDTA), polyoxyethylene
strearyl ether (PSE) and polyethoxylated castor oil (PCO) are
examples of such compounds with well-known ocular surface
toxic effects. 15,16
Intraocular lenses such as ocular implants can be modified
to provide a controlled release of pharmacological agents and
prevent intraocular inflammation, infection and lens posterior
capsule opacification. There are already available in the market
injectable intraocular implants to treat several chronic eye
diseases ensuring a drug sustained release for 2.5-3 years:
IluvienTM (Alimera Sciences Inc.) for diabetic macular edema,
RetisertÒ (Baush &Lomb) and OzurdexÒ (Allergan) for
chronic non-infectious posterior uveitis and DurasertTM (Pfizer
Inc.) for glaucoma. 14, 17- 18
Several drug retention strategies have been pursued to
minimize the need for repeated treatments, especially in chronic
diseases. They comprise viscosity-enhancing polymers, “in situ”
gels undergoing phase transition from liquid to gel under
physiological conditions, mucoadhesives and mucus-covered
mucosal epithelial membranes, and nanoparticles drug-delivery
systems as submicron structures in which drugs can be attached
or encapsulated. Submicron-sized liposomes (ssLips) formulated
as eye drops were effective in delivering coumarin-6 to the reti-
na. Ocular inserts are drug-loaded devices designed to deliver a
sustained drug release in direct contact with the conjunctiva or
with the cornea and finally dissolve, erode or biodegrade.
Ocusert® (Alza Corporation, Palo Alto) could deliver pilocarpine
at either 20 ìg/h or 40 ìg/h. Ocufit SR® (Escalon® Medical Corp)
is a silicone elastomer rod-shaped device to be placed in the
lower conjunctival fornix. Minidisc Ocular Therapeutic System
(OTS, Bausch & Lomb, UK) is a drug-loaded polymer disc (4–5
mm) to be placed on the upper or lower fornix and deliver
gentamicin or sulfisoxazole over a period of 3 to 14 days. The
human amniotic membrane can be used as a drug-loaded ocular
device to deliver ofloxacin for up to 7 hours in vitro. CLs are
hard or soft ocular insert devices designed to fit directly onto the
cornea, up to now, mainly to correct ametropia. SCLs are
produced from hydrophilic or hydrophobic hydrogel polymers.
Table 1
 Strategies to promote drug bioavailability.
Adapted from Morrison and Khutoryanskiy 14
STRATEGIES TO PROMOTE DRUG BIOAVAILABILITY
Solubility and Penetration Enhancement




Implantable devices able to reside within the eye.
Retention Strategies
Viscosity-enhancing polymers, in situ gels and bio-adhesive
formulations.
Ocular inserts to place and retain the agent in immediate
contact with target tissue.
They can soak a large volume of aqueous solution relative to
their anhydrous form with sufficient pharmaceutically active
content able to diffuse from the polymer matrix into the tear
film, bathe the eye and interact with the ocular tissue. Antibiotic
and anti-inflammatory medication can be combined with a
bandage CL to effectively manage ocular trauma, post-surgery
conditions and promote epithelization.  Several commercially
available CLs were FDA approved to serve this purpose: Pure
Vision (balafilcon A, Bausch+Lomb), Acuvue 2 (etafilcon A,
Vistakon Inc.), Acuvue Oasys (senofilcon A, Vistakon Inc.), and
Air Optix Night & Day (lotrafilcon A, Alcon). 13-15, 19
Generating Contact Lense based Drug Controlled Release
Systems and Clinical Applications
The three main objectives underlying the development of
DCRS based on CLs to enhance effective drug delivery are:
1. To improve and extend CL wear tolerance by incorpo-
rating anti dry eye and allergy agents’ formulations.
2. To enhance patient compliance and reduce unwanted
systemic side effects especially in chronic diseases such
as glaucoma and dry eye whilst correcting ametropia.
3. To manage corneal wound healing such as “bandage
lenses” by incorporating antimicrobial or anti-inflamatory
agents. 13
Offering a higher drug bioavailability to the cornea than
conventional forms of treatment, CLs look the ideal carrier for
ocular medication. Several strategies have been attempted to
extend drug residence time and improve bioavailability including:
soaking, incorporation of diffusion barriers, functional
monomers, ligands, colloidal nanoparticles, molecular imprinting,
and surface multi layering. 15  (Figure 1).
CLs drug soaking is the earliest and simplest procedure to
prepare drug lense combinations. The hydrophilic matrix of SCLs,
ranging from 30 to 80 percent water, can absorb the drug from a
soaking solution till equilibrium and then release it by simple
diffusion when inserted in the eye. Intraocular pressure
decreased from 55.6 to 30.0 mm Hg after two hours’ use of a 1%
pilocarpine loaded CL following this process, to treat acute angle
closure glaucoma.  Assays with SCL hydrogels of poly (2-
hydroxyethyl methacrylate) (pHEMA) loaded in drug solutions
containing, pilocarpine, levofloxacin, chlorhexidine, timolol and
dexamethasone have demonstrated dynamic drug diffusion.
More recently epidermal growth factor-soaked CLs have shown
a positive therapeutic effect in a rabbit model wound healing
and improved the healing time in non-significantly inflamed
Figure 1: Schematic diagram of strategies commonly used to improve
drug release behavior from drug loaded CLs: 1- Soaking, 2-
Incorporation of diffusion barriers such as vitamin E, 3- Incorporation
of ligands/functional monomers in the polymeric matrix, 4- Molecular
imprinting 5- Incorporation of drug-loaded nanoparticles or other
colloidal nanostructured systems and 6- Surface coating by multi-
layering colloidal nanoparticles and ligands.
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corneas of patients with delayed corneal re-epithelization when
compared to saline-soaked CLs. 21-28
SCL drug absorption and release is drug specific. Drug
uptake depends on factors such as CL thickness and water
content, the drug’s molecular weight and gel matrix solubility.
Similar CLs could absorb 7 to 8 mg of cromolyn sodium whereas
only 0.07 mg of dexamethasone sodium phosphate. For most
tested compounds such as prednisolone, pilocarpine, and
ciprofloxacin, release by hydrophilic CLs was complete within 1
to 3 h, whereas ketotifen fumarate eluted from SHCLs over
approximately 4-5 hours. 8,29
In vitro release studies are commonly carried out in
conditions that are far from simulating the physiological delivery
conditions. In order to more reliably predict the drug’s release
kinetics in the eye, it is crucial to develop microfluidic models
that mimic, as closely as possible, the hydrodynamic conditions
of the eye such as volume of liquid in contact with the ocular
surface and tear flow rate. 30
Although simple, the drug loading method by soaking is
limited by the rapid drug release and will be more appropriate
to produce daily disposable therapeutic CLs. Research is now
focused on novel approaches to control drug release. Several
processes have been attempted to create additional barriers to
CL drug release and generate ocular surface drug delivery over
time at the correct dosage. 31
Vitamin E aggregates incorporated within SHCLs block
UV radiation and create a hydrophobic diffusion barrier to rapid
drug diffusion without compromising proper oxygen
permeability, ion permeability, and light refractive properties.
Vitamin E loading proved to be very effective in increasing release
duration of lidocaine, CyA, timolol, levofloxacin, chlorhexidine,
dorzolamine, dexpantenol, betaine, dexamethasone and
betamethasone, from hours to several days. 32-37
Research on dry eye management has been increasingly
focusing on the inflammatory aspect and CyA was FDA
approved to treat moderate-to-severe dry eye disease. SHCLs
were able to keep CyA delivery rates within therapeutic levels
for 14 days. Vitamin E loaded CLs provided a CyA extended
release up to one month. In vivo transport and toxicity studies
are needed to assure the benefits of extended wear CLs for this
purpose.  CLs loaded with 30% of vitamin E showed a
dexamethasone release time extended to 7-9 days for
ACUVUE(®) OASYS™, NIGHT&DAY™ and O(2)OPTIX™,
which is a 9 to 16 fold increase compared to drug release duration
by CLs without vitamin E loading  11, 38, 39
Serro et al. also showed that vitamin E loaded commercial
CLs presented a significant increase of clorhexidine and
levofloxacin release duration while retaining critical properties
for in vivo use. 35
Weak interactions between drugs and polymer ligands
include hydrogen bonds, electrostatic interactions and host-guest
interactions. They can induce drug loading and controlled release
by ions in solution. Based on ion-exchange reaction these ligands
store anionic or cationic drugs depending on the charge of their
functional groups. Hydrogels containing cationic functional
groups suit the delivery of anionic drugs whereas those containing
anionic functional groups the release of cationic drugs. However,
sustained release of these ions ligand-containing hydrogels last
only several hours, making them unsuitable for extended drug
delivery. Cyclodextrins (CDs) have hydrophobic internal cavities
that can include “guest” drug molecules.  Poly(2-hydroxyethyl
methacrylate) hydrogels containing â-cyclodextrin (pHEMA/â-
CD) have been investigated as a platform for sustained release
of ophthalmic drugs. Incorporation of hyaluronic acid into
hydrogels allowed timolol and ciprofloxacin release for a
prolonged period. 39- 42
The incorporation of functional monomers able to interact
with the drug in the hydrogels may prolong release duration.
Increased interaction of the drug with these monomers delays
its diffusion from the hydrogel. For example, the combination of
the hydrophobic monomer 3-(trimethoxy-silyl) propyl
methacrylate and the ionic monomer N,N-dimethylaminoethyl
methacrylate improved insulin and protamine loading and
allowed their extended release from pHEMA SCLs. Andrade-
Vivero et al. reported that the incorporation of 4-vinyl-pyridine
(VP) and N-(3-aminopropyl) methacrylamide (APMA)
monomers increased the amount of loaded ibuprofen up to 10-
fold and diclofenac up to 20-fold without compromising lens
properties. The sustained drug release process from pHEMA-
VP lasted for at least 24 hours for ibuprofen and almost 1 week
for diclofenac. Kim et al. designed a SH comprising a hydrophilic
monomer N,N-dimethylacrylamide (DMA) and a silicone
monomer methacryloxypropyltris (trimethylsiloxy)silane (TRIS),
with a new macromer bis- alpha, omega-(methacryloxypropyl)
polydimethylsiloxane (MW 7152). This extended wear SHCL
enabled an extended release of timolol, dexamethasone, and
dexamethasone 21-acetate (hydrophobic and hydrophilic drugs)
from 2 weeks to 3 months depending on the composition of the
hydrophobic and hydrophilic components. Corneal abscess and
opacity were almost healed after wearing a gatifloxacin loaded
P(HEMA-co-MAA) hydrogel CL for 48 hours. 8, 11, 43-45
Colloidal nanoparticles are submicron-sized particles either
encapsulating or mixed with the agent molecules.  Two common
forms are lipid spheres (liposomes) and colloidal polymeric
nanoparticles. Due to their excellent biocompatibility, liposomes
are promising candidates for dispersion or surface immobilization
on CLs Nanoparticles are specifically designed to present high
affinity for the drug of interest, being either dispersed in the
matrix or coating the surface of the CL. Once inserted in the eye
the agent diffuses out of the CL matrix away from the
nanoparticle towards the tear film. Nanosphere - encapsulated
ciprofloxacin incorporated into HEMA-based CL (Acuvue;
Johnson & Johnson Vision Care, Inc., Jacksonville, FL) provided
a sustained and effective bactericidal activity. Timolol-loaded
nanoparticle incorporated in HEMA-based CLs maintained drug
stability under refrigerated conditions and the temperature
change promoted the drug release upon CL insertion.
Nanoparticle loaded gels released timolol in phosphate buffered
saline (PBS) for 2-4 weeks within therapeutic levels, looking
promising for extended drug release applications. Sustained and
effective bactericidal activity was provided by conventional
hydrogel CLs incorporating nanosphere-encapsulated
ciprofloxacin. 8, 11, 46-54
Molecular imprinting consists of creating a template based
on a macromolecular memory within a flexible network with a
higher affinity towards a drug molecule. Functional monomers
thus generated, should favorably interact with a specific drug
and this change in formulation improves drug uptake and
prolongs delivery. Commonly used monomers for CLs include
acrylic acid (AA), acrylamide (AM), methacrylic acid (MAA),
methyl methacrylate (MMA) and N-vinyl 2-pyrrolidone (NVP).
Increased partitioning due to imprinting depends on the fraction
of the functional monomers in CLs, temperature, pressure, drug-
functional monomer ratio, initiator concentration and degree of
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crosslinking.  Imprinted hydrogels composed of HEMA and
small amounts of MAA presented higher timolol uptake (12mg
timolol/g dry hydrogel) than non-imprinted gels and a drug
release during 8–10h. Ketotifen fumarate loading was 6-fold
greater in the highest functionalized imprinted hydrogels and
their diffusion coefficients were 10 times lower than in less
functionalized hydrogels. 55-59
Timolol is the most commonly used drug in imprinting
studies but hyaluronic acid, diclofenac, ibuprofen, norfloxacin,
ketotifen fumarate, acetazolamide, ciprofloxacin and
prednisolone have also been studied.7,11, 60-62
Despite being different from typical functional monomers
used in molecular imprinting, hyaluronic acid proved to be useful
in modifying the drug release curve from model SH lenses having
shown a controlled release over 24 hours. As a wetting agent,
hyaluronic acid enhances comfort and additionally promotes
corneal wound healing and epithelial cell migration,.63
Layer-by-layer platforms have been applied for drug
delivery due to its simple and mild aqueous manufacturing
conditions at room temperature. By sandwiching a poly[lactic-
co-glycolic acid] layer (PLGA) in a 100 micron thick gel extended
release of timolol and dexamethasone was achieved from 2 weeks
to 3 months . Hydrogel containing a layer of ciprofloxacin loaded
PLGA film sandwiched between layers of pHEMA was able to
release medication for an extended period and prevent bacterial
growth. Chitosan/alginate layers were tested to control the release
of different ophthalmic drugs from a silicone-based hydrogel. A
double layer of this coating led to a controlled release of diclofenac
for one week. 64- 66
Perspectives and Summary
Research in CL based DCRS shows promising results in a
wide variety of situations such as a potential application to treat
posterior segment diseases and a platform to culture and transfer
limbal cells to treat limbal stem cell deficiency. In vitro experi-
mental results and mathematical modeling suggested that a single
CL worn for about 2 hours achieved the same therapeutic effects
as hourly instillation of eye drops in controlling corneal cysteine
crystals deposition in cystinosis. CL based DCRS can work as a
responsive drug delivery platform to environmental triggers such
as temperature, pH, ionic interactions or light stimulation. They
can assist in the management of corneal persistent epithelial
defects by using bandage CLs soaked in vibronectine, a protein
that expedites corneal epithelial wound healing and in treating
fungal keratitis with CLs as drug reservoir releasing agents for
up to 21 days. 67-74
Nevertheless, several challenges remain to extend this
treatment option to the general population due to CLs’ increased
risk of infection, to processing, storage, safety, cost-benefit and
regulatory issues. To our knowledge, a ketotifen-CL combination
(Vistakon/Johnson&Johnson) for patients with allergic
conjunctivitis (NCT 00432757) and a plant polysaccharide
lubricant alginic acid–CL combination for dry eye CL wearers
(NCT 01918410) represent an effort in the clinical application of
these systems. 50, 75-77
In summary CLs as DCRS are emerging as an effective
treatment option for several ocular disorders, including those
that can compromise a comfortable and safe CL wear such as
glaucoma, allergy and dry eye. By improving bioavailability and
effective localized drug delivery these systems can enhance patient
compliance, reduce overdosing and avoid unwanted side effects,
whilst correcting ametropia. They promote the safe and
comfortable wearing of CLs by the incorporation of wetting
agents, provide a timely and efficient medication release in corneal
epithelial defect, treat infection and promote healing.
Drug incorporation in CLs can be achieved with several
techniques from which soaking is the earliest. There is exciting,
ongoing research on techniques to increase drug retention on
ocular surface and obtain a sustained release within therapeutic
levels. The incorporation of vitamin E, ligands, functional
monomers, drug-loaded nanoparticles, molecular imprinting, and
layering are under study. An ideal CL drug delivery system should
involve high drug loading and controllable drug release without
compromising the biomaterial properties of CLs.
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